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SHORT COMMUNICATION
Primary cutaneous B-cell lymphomas (PCBCL) are rare 
skin-defined non-Hodgkin lymphomas with no extracuta-
neous involvement at the time of diagnosis. They are clas-
sified into 3 major entities in the 2008 WHO-EORTC joint 
classification (1). These 3 most common types include 
primary cutaneous follicle centre lymphoma (PCFCL), 
primary cutaneous marginal zone lymphoma (PCMZL) 
and primary cutaneous diffuse large B-cell lymphoma, 
leg type (PCLBCL-LT). PCBCL constitute approximately 
25% of all skin lymphomas. It is important to distinguish 
between PCBCL and systemic B-cell lymphomas with 
skin involvement, since most PCBCL are low-grade 
malignancies with a 5-year survival of up to 95–99% (2).
The current treatment options for PCBCL (besides lo-
cal treatments, e.g. topical corticosteroids, nitrogen mus-
tard, bexarotene) include radiotherapy, surgical excision, 
chemotherapy, interferon-α and monoclonal antibodies 
(3–5). For aggressive forms, polychemotherapy is used. 
Rituximab is a chimeric monoclonal immunoglobu-
lin G antibody targeting CD20, which is expressed on 
normal and tumour B cells (6). Intravenous rituximab 
is commonly used in systemic low-grade B-cell non-
Hodgkin lymphomas (7), whereas intralesional rituximab 
is being increasingly used as an alternative to conventio-
nal treatments (radiation or surgery) (5). No randomized 
studies are available on the efficacy of intralesional 
rituximab treatment, but there are some reports of the 
effect of intralesional rituximab in PCBL (8–15).
PATIENTS AND METHODS
Of  the 9 patients, 5 were male and 4 female. The mean age at diag-
nosis was 58 years. Three patients had PCMZL and 6 had PCFCL, 
confirmed by histology and immunohistology performed at the 
Dermatopathology Unit of Helsinki University Central Hospital 
at the time of diagnosis. None of the patients had signs of lymph 
node or systemic involvement, based on computed tomography 
(CT). According to the ISCL/EORTC proposal on tumour-node-
metastasis (TNM) classification of cutaneous lymphomas other 
than mycosis fungoides/Sézary syndrome, our cases varied in 
classes T1a–T2a, N0M0 (16). In all cases CD20 staining was po-
sitive and Bcl-2 was positive in marginal zone lymphoma-lesion 
patients. An immunoglobulin lambda gene clonal proliferation was 
confirmed in all of the patients with marginal zone lymphoma. 
The basic treatment protocol was to inject 2 ml rituximab 
(Mabthera (10 mg/ml, Genetech Inc, Oseanside, USA)) intrale-
sionally 3 times for a week for 4 weeks. This treatment schedule 
was modified in some cases, as described in the results section. 
With increased experience, we added pre-injectional paracetamol 
prophylaxis to the protocol. We followed each patient from the 
time of diagnosis until 28 Feb 2015.
RESULTS
Nine patients with multiple cutaneous lesions or multi-
ple cutaneous locations of PCBCL during 2008 to 2014 
were treated with intralesional rituximab. Six patients 
had a solitary lesion. The most common therapy prior 
to intralesional rituximab was surgery, which 5 patients 
had undergone (Table I).
Six patients received only one rituximab treatment 
cycle, and 3 patient received multiple cycles. Prima-
rily, all patients achieved complete response (CR) with 
intralesional rituximab. If re-treatment was needed, it 
was as successful as primary treatment. Follow-up time 
varied from 6 months to 8 years. The mean follow-up 
time was 4.1 years. Until the end of follow-up period 5 
out of 9 patients had experienced relapse. In all patients 
relapses occurred in the same anatomical location as the 
primary lesion(s). The time to relapse after treatment 
is shown in Table I.
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Table I. Main characteristics of patients with primary cutaneous marginal zone lymphoma (PCMZL) and primary cutaneous follicle 











M/64 PCMZL/T1a S+R 3 360 3 Thigh CR Yes/5–25 8.3
F/63 PCFCL/T2a S 2 344 1 Neck/back CR Yes/34 8.0
M/19 PCFCL/T2a S+R 4 155 4 Head CR Yes/6–18 1.7
M/66 PCMZL/T2a None 1 600 3 Upper arm CRa Yes/11 6.3
F/52 PCFCL/T1a None 1 147 1 Torso CR No 3.2
M/71 PCMZL/T1a S 1 240 1 Shoulder/neck CR Yes/24 6.25
F/71 PCFCL/T1a S 1 275 1 Back CR No 1.7
M/41 PCFCL/T1a None 1 120 1 Head CR No 0.5
F/76 PCFCL/T1a None 1   40 1 Head CR No 0.5
aLater developed papular eruption and mantle cell lymphoma. S: surgery; R: radiation.
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Our primary protocol was to administer rituximab, in 
a dose of approximately 2 ml (10 mg/ml) per lesion 3 
times a week for 4 weeks, depending on the size of the 
lesions (Fig. 1). In some patients it was not possible or 
necessary to follow this protocol: if the lesions were on 
the forehead or the skull, it was technically difficult to 
inject a large volume of rituximab. Also, in 4 patients 
the lesions responded early in the cycle and not all in-
jections were needed. The cumulative dose of injected 
rituximab ranged from 60 to 600 mg depending on the 
patient. Two patients also underwent radiation therapy 
after relapse with rituximab. The side-effects were 
minor irritation on the injection side and fever (4/9) up 
to 38°C on the day of treatment. Due to this, we added 
paracetamol prophylaxis to the treatment protocol. One 
patient developed urticarial-like lesions on and around 
the injection site at the beginning of his 4th cycle.
Two patients (one with PCFCL and one with PCMZL) 
had a previous history of Borrelia burgdorferi infection 
and one patient had had 3 lymphocytomas before the 
PCFCL diagnosis. One lesion (PCMZL) tested positive 
with borrelia-polymerase chain reaction (PCR) and ri-
tuximab treatment was effective only after administration 
of amoxicillin, 2 g/day for 21 days. One patient with 
PCMZL later developed systemic mantle cell lymphoma.
DISCUSSION
PCBCLs are indolent lymphomas, which have a good 
prognosis and a tendency to relapse. The existing 
guide lines are based on retrospective studies and small 
case report series (5). Currently, local radiotherapy and 
surgery are recommended as first-line therapy in both 
PCFCL and PCMZL, whereas intralesional rituximab 
is considered as a second-line, alternative therapy. 
Considering the indolent nature of the disease, the 
treatments should not be devastating and even a “treat 
as needed” concept is acceptable. The good cosmetic 
results of intralesional rituximab injections favour this 
treatment mode over surgery and radiation therapy. 
Intralesional rituximab is also well tolerated with mi-
nor side-effects. One of the most common side-effects 
of intravenous rituximab is short-term fever, occurring 
in 4 of our patients regardless of paracetamol prophy-
laxis. One of our patients developed an urticarial-type 
reaction and one a hydroa-vacciniforme-like eruption.
The number of patients reported here (i.e. 9) is small, 
but as far as we know it includes all patients treated with 
intralesional rituximab in Finland. The largest previous 
study reported is by Penate et al. (9) with 35 patients. In 
this study, most of the patients had previous treatments 
and the most common sites of the lesions were head, 
neck and trunk. The CR rate varied between 65% and 
78% and median follow-up time was 84 weeks. Our 
results reflect the same tendency, but in total, we fol-
lowed up patients for 8 years.
Previous reports of PCBCL treated with intralesional 
rituximab have shown a relatively high incidence of 
recurrences. This is related to the tendency of PCBCL 
to relapse. We have also treated one large facial lymp-
hocytoma with intralesional rituximab with good results 
(data not shown). Our results show that intralesional 
rituximab injections are a reasonable option for radia-
tion therapy in selected cases. The treatment can be 
repeated several times and it is more cost-effective than 
intravenous rituximab treatment. Relapses are common 
and different treatment modalities and maintenance 
therapies may be considered in the future.
The authors declare no conflicts of interest.
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